Clinical Use of Aromatase Inhibitors in Adult Males

Buy Lab Tests Online

madman

Super Moderator
why would you take AI if your e2 is not way too high? once your e2 gets high if you indeed want to lower it for whatever reason you take a small dose AI to prevent it test from aromatising on next couple of days.. thats true it doesnt affect e2 that was already there but if you take too much it can crash on you since after AI if the dose isnt very small you will not generate any estrogen.. thats how crash occurs
i totally belive when somebody says .25mg crashed them some are very sensitive to anastrozole.. some need like 0.5mg twice weekly to keep their e2 in range while others crash from small .25mg. Vince Carter if .25 wouldnt crash you doesnt mean it wouldnt crash other guys


Every time in every post you always speak of one experiencing a crash as if e2 is non existent!




Brief Introduction to the AIs


The enzyme aromatase is found in the endoplasmic reticulum of the estrogen-producing cell and is the key enzyme in estrogen biosynthesis. The enzyme aromatase is able to convert testosterone into estradiol and androstenedione into estrone. Aromatase activity has been demonstrated in gonads, placenta, brain[33], adipose tissue[34,35], muscle [36], hair [37], bone [38], and vascular tissue [39].


AIs are classified as either type 1 (steroidal) or type2 (nonsteroidal). Examples of steroidal AIs are testolactone, formestane, and exemestane, which inhibit aromatase activity by mimicking the substrate androstenedione. They irreversibly inhibit the aromatase enzyme by covalently binding to it; as such they are also known as “suicidal inhibitors.”

Nonsteroidal AIs inhibit enzyme activity by reversibly binding with the heme iron of the enzyme, resulting in competitive inhibition. Examples of nonsteroidal AIs are aminoglutethimide, fadrozole, anastrozol, letrozole, and vorozole (Table 1).


AIs are further classified into generations based on their efficacy. First generation inhibitors (e.g., aminoglutethimide) are relatively weak and nonspecific, whereas third generation AIs (e.g., letrozole and anastrozole) are most potent, most specific, and least toxic. Their pharmacokinetic properties (t1/2 of 48 hours for ansatrozole and letrozole and t1/2 of 27 hours for exemestane) allow for a once-daily dosing schedule. Their selective inhibitory properties negate the need for corticosteroidal or mineralocorticoid supplementation, which is essential for the nonspecific AI aminogluthimide. The second generation AIs are in between with regard to potency, specificity, and toxicity (e.g., formestane and fadrozole). Third generation AIs have been reported to have close to 100% inhibition of the enzyme, but this is not the case in males. In men, third-generation AIs will decrease the mean plasma estradiol/testosterone ratio by 77% [41,42].This can be explained by the higher plasma concentration of testosterone in eugonal adult men compared with women. .Because inhibition of aromatase is dose dependent, aromatase is less suppressed in the testis compared with adipose and muscle, thus explaining the incomplete efficacy of aromatase inhibition in males. The molar ratio of testosterone to AI and testicular aromatase activity is higher compared with adipose and muscle tissue. As mentioned earlier in this article, low estradiol levels are detrimental to bone health and sexual function. Thus, this incomplete suppression may be advantageous to men,and this lowers the risk of the potential side effects of AIs. Long-term use of potent AIs reduces circulating estradiol levels by 88% [43]. This is associated with adverse effects on bone [44,45] and could possibly be associated with increased body fat in men [22].
 

Attachments

  • DEC16-AI-tan2014.pdf
    139.4 KB · Views: 136
Defy Medical TRT clinic doctor
With studies conducted for every drug, the dose administered must always be considered. Especially when claims of a given percentage of inhibition are derived.

"The dose makes the poison"
 

madman

Super Moderator
Aromatase inhibitors in men: effects and therapeutic options




Aromatase inhibitors
Aromatase inhibitors are classified as either steroidal or nonsteroidal, or as first, second or third generation. Steroidal inhibitors such as formestane and exemestane inhibit aromatase activity by mimicking the substrate androstenedione. Nonsteroidal enzyme inhibitors such as anastrozole and letrozole inhibit enzyme activity by binding with the heme iron of the enzyme. First-generation aromatase inhibitors such as aminoglutethimide are relatively weak and nonspecific; they can also block other steroidogenic enzymes necessitating adrenal steroid supplementation. Third-generation inhibitors such as letrozole and anastrozole are potent and do not inhibit related enzymes. They are well tolerated and apart from their effects on estrogen metabolism their use does not appear to be associated with important side effects in postmenopausal women [27]. Although aromatase inhibition by anastrozole and letrozole is reported to be close to 100%, administration of these inhibitors to men will not suppress plasma estradiol levels completely. In men third-generation aromatase inhibitors will decrease the mean plasma estradiol/testosterone ratio by 77% [28,29]. This finding probably relates to the high plasma concentrations of testosterone, a major precursor for estradiol synthesis in adult men. As aromatase inhibition is dose dependent it has been suggested that aromatase is less suppressed in the testis compared to adipose and muscle tissue, explaining the incomplete efficacy of aromatase inhibition in men. Aromatase activity is high in the testes and the molar ratio of testosterone to letrozole is much higher in the testes compared with adipose and muscle tissue. When testicular testosterone and estradiol synthesis are suppressed and testosterone is administered exogenously in combination with letrozole, however, the estradiol/testosterone ratio is suppressed by 81% [30], which is only marginally different from the suppression of this ratio in intact men after treatment with letrozole. This incomplete suppression may be regarded as advantageous for it prevents excessive reduction of estrogen levels in men and the possible associated adverse effects. In postmenopausal women with breast carcinoma, long-term use of potent aromatase inhibitors reduces circulating estradiol levels by 88% [31] and is associated with adverse effects on bone [2,3]. Due to the much higher estrogen levels in treated men it remains to be determined whether this also holds true for men.






True and the take home point....."administration of these inhibitors to men will not suppress plasma estradiol levels completely"
 

Attachments

  • DEC24-AI-1477-7827-9-93.pdf
    257.7 KB · Views: 113
Buy Lab Tests Online

Sponsors

bodybuilder test discounted labs
Defy Medical Telemedicine hormones
Discounted lab tests
TRT in UK Balance my hormones
Testosterone books nelson vergel
Free Testosterone Book
Register on ExcelMale.com
Trimix HCG Offer Excelmale
Thumos USA men's mentoring and coaching
Testosterone TRT HRT Doctor Near Me

Online statistics

Members online
7
Guests online
5
Total visitors
12

Latest posts

Top